LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $97.60.

Several brokerages have recently commented on LMAT. Barrington Research reaffirmed an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Tuesday, September 23rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald increased their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th.

Insider Activity

In related news, Director David B. Roberts sold 10,815 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director owned 17,976 shares in the company, valued at approximately $1,660,802.64. This trade represents a 37.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,815 shares of company stock worth $11,280,206. Insiders own 9.50% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. GAMMA Investing LLC boosted its position in LeMaitre Vascular by 7,486.5% in the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock valued at $4,519,000 after buying an additional 53,154 shares in the last quarter. NBC Securities Inc. acquired a new stake in LeMaitre Vascular in the first quarter valued at approximately $36,000. Vest Financial LLC acquired a new stake in LeMaitre Vascular in the first quarter valued at approximately $1,470,000. Compass Planning Associates Inc boosted its position in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier’s stock valued at $988,000 after buying an additional 5,623 shares in the last quarter. Finally, Wesbanco Bank Inc. acquired a new stake in LeMaitre Vascular in the first quarter valued at approximately $470,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.1%

Shares of LMAT opened at $87.85 on Friday. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The firm’s 50 day moving average is $91.66 and its 200-day moving average is $86.28. The stock has a market capitalization of $1.99 billion, a PE ratio of 42.65, a P/E/G ratio of 2.26 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. During the same period last year, the firm earned $0.52 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.